610 related articles for article (PubMed ID: 18180926)
1. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
2. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
3. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer.
Raitanen MP; Kaasinen E; Lukkarinen O; Kauppinen R; Viitanen J; Liukkonen T; Tammela TL;
Urology; 2001 Apr; 57(4):680-4. PubMed ID: 11306380
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
Raitanen MP; Hellström P; Marttila T; Korhonen H; Talja M; Ervasti J; Tammela TL;
Eur Urol; 2001 Oct; 40(4):422-6. PubMed ID: 11713397
[TBL] [Abstract][Full Text] [Related]
5. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
[TBL] [Abstract][Full Text] [Related]
6. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
9. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
10. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
[TBL] [Abstract][Full Text] [Related]
11. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
[TBL] [Abstract][Full Text] [Related]
14. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
Leyh H; Mazeman E
Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
16. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E
Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097
[TBL] [Abstract][Full Text] [Related]
17. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
18. Utility of the BTA stat test kit for bladder cancer screening.
Nasuti JF; Gomella LG; Ismial M; Bibbo M
Diagn Cytopathol; 1999 Jul; 21(1):27-9. PubMed ID: 10405804
[TBL] [Abstract][Full Text] [Related]
19. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
Serretta V; Pomara G; Rizzo I; Esposito E
Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
[TBL] [Abstract][Full Text] [Related]
20. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]